Aya Fujishiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aya Fujishiro has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Akifumi Takaori-Kondo
Department of Hematology and Oncology, Kyoto University Graduate School for Medicine, Kyoto, Japan
2 shared publicationsAkira Andoh
Division of Gastroenterology and Hematology, Department of Medicine, Shiga University of Medical Science, Otsu, Japan
2 shared publicationsKaoru Tohyama
Department of Laboratory Medicine, Kawasaki Medical School, Kurashiki, Japan
2 shared publicationsMasaki Iwasa
Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
2 shared publicationsSumie Fujii
Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
2 shared publicationsTaira Maekawa
Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
2 shared publications
Latest Publications
- 15 September 2020
- Published by Springer Nature in International Journal of Hematology
- Vol. 112 (4) , 599-602
Correction to: Menatetrenone facilitates hematopoietic cell generation in a manner that is dependent on human bone marrow mesenchymal stromal/stem cells
In the original publication of the article, the Figs. 4 C, F and 5 B, C were published with unexpected appearance of dots.
- 15 September 2020
- Published by Springer Nature in International Journal of Hematology
- Vol. 112 (4) , 599-602
Correction to: Menatetrenone facilitates hematopoietic cell generation in a manner that is dependent on human bone marrow mesenchymal stromal/stem cells
In the original publication of the article, the Figs. 4 C, F and 5 B, C were published with unexpected appearance of dots.
- 22 June 2020
- Published by Springer Nature in International Journal of Hematology
- Vol. 112 (3) , 316-330
Menatetrenone facilitates hematopoietic cell generation in a manner that is dependent on human bone marrow mesenchymal stromal/stem cells
Vitamin K2 in the form of menatetrenone has clinical benefits for osteoporosis and cytopenia. Given the dominant role of mesenchymal-osteolineage cells in the regulation of hematopoiesis, we investigated whether menatetrenone alters the hematopoiesis-supportive capability of human bone marrow mesenchymal stromal/stem cells (BM-MSCs). Menatetrenone up-regulated fibronectin protein expression in BM-MSCs without affecting their proliferation and differentiation capabilities. In addition, menatetrenone treatment of BM-MSCs enhanced generation of the CD34+ cell population in co-cultures through acceleration of the cell cycle. This effect was associated with cell–cell interactions mediated by VLA-4 and fibronectin. This proposal was supported by cytokine array and quantitative real-time PCR analyses, in which there were no significant differences between the expression levels of hematopoiesis-associated soluble factors in naïve and menatetrenone-treated BM-MSCs. Profiling of hematopoietic cells in co-cultures with menatetrenone-treated BM-MSCs demonstrated that they included significantly more CD34+CD38+ hematopoietic progenitor cells and cells skewed toward myeloid and megakaryocytic lineages than those in co-cultures with untreated BM-MSCs. Notably, myelodysplastic syndrome-derived cells were induced to undergo apoptosis when co-cultured with BM-MSCs, and this effect was enhanced by menatetrenone. Overall, our findings indicate that pharmacological treatment with menatetrenone bestows a unique hematopoiesis-supportive capability on BM-MSCs, which may contribute to the clinical improvement of cytopenia.
- 22 June 2020
- Published by Springer Nature in International Journal of Hematology
- Vol. 112 (3) , 316-330
Menatetrenone facilitates hematopoietic cell generation in a manner that is dependent on human bone marrow mesenchymal stromal/stem cells
Vitamin K2 in the form of menatetrenone has clinical benefits for osteoporosis and cytopenia. Given the dominant role of mesenchymal-osteolineage cells in the regulation of hematopoiesis, we investigated whether menatetrenone alters the hematopoiesis-supportive capability of human bone marrow mesenchymal stromal/stem cells (BM-MSCs). Menatetrenone up-regulated fibronectin protein expression in BM-MSCs without affecting their proliferation and differentiation capabilities. In addition, menatetrenone treatment of BM-MSCs enhanced generation of the CD34+ cell population in co-cultures through acceleration of the cell cycle. This effect was associated with cell–cell interactions mediated by VLA-4 and fibronectin. This proposal was supported by cytokine array and quantitative real-time PCR analyses, in which there were no significant differences between the expression levels of hematopoiesis-associated soluble factors in naïve and menatetrenone-treated BM-MSCs. Profiling of hematopoietic cells in co-cultures with menatetrenone-treated BM-MSCs demonstrated that they included significantly more CD34+CD38+ hematopoietic progenitor cells and cells skewed toward myeloid and megakaryocytic lineages than those in co-cultures with untreated BM-MSCs. Notably, myelodysplastic syndrome-derived cells were induced to undergo apoptosis when co-cultured with BM-MSCs, and this effect was enhanced by menatetrenone. Overall, our findings indicate that pharmacological treatment with menatetrenone bestows a unique hematopoiesis-supportive capability on BM-MSCs, which may contribute to the clinical improvement of cytopenia.